Key Takeaways
- •The race for more convenient GLP-1-based obesity treatments is accelerating.
- •This article provides scientific context on the drug delivery technologies involved, the competitive dynamics, and the b
- •The active ingredient in Lilly’s current weight loss and diabetes drugs is tirzepatide, a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Monthly Obesity Injections: Eli Lilly’s Long-Acting Ambition and the Peptron-Camurus Race
The race for more convenient GLP-1-based obesity treatments is accelerating. Eli Lilly, the maker of the blockbuster weekly injections Mounjaro and Zepbound, is now working on a monthly obesity shot, according to a report from the South Korean media outlet Chosunbiz. The move immediately drew attention to two biotech firms competing to secure a licensing deal with the pharmaceutical giant: South Korea’s Peptron and Sweden’s Camurus. Both companies are developing long-acting formulations that could enable monthly dosing, a significant leap from the current once-weekly standard.
This article provides scientific context on the drug delivery technologies involved, the competitive dynamics, and the broader implications for the weight management market.
The Challenge of Moving from Weekly to Monthly Dosing
The active ingredient in Lilly’s current weight loss and diabetes drugs is tirzepatide, a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Its half-life is already unusually long for a peptide approximately five days, which allows for once-weekly subcutaneous injection. But extending that interval to a full month poses formidable technical hurdles.
The core problem is drug release kinetics. To maintain therapeutic concentrations over 28 days, the peptide must be released from its delivery vehicle at a constant, predictable rate. If release is too fast, peak levels might cause excessive side effects such as nausea, vomiting, or hypoglycemia. If release is too slow, the drug concentration may fall below the effective threshold, allowing blood glucose and appetite to rebound.
Two main technological approaches are used to achieve sustained release of peptides: biodegradable polymer microspheres and lipid-based liquid crystal systems. Both aim to protect the peptide from rapid degradation and to control its diffusion into the surrounding tissue.
Peptron’s Sustained-Release Expertise
Peptron, based in Daejeon, South Korea, has built its reputation on sustained-release drug delivery platforms. The company’s core technology involves encapsulating peptides in biocompatible and biodegradable polymers, typically poly(lactic-co-glycolic acid) (PLGA) microspheres. PLGA has been used for decades in long-acting injectables, including leuprolide acetate for prostate cancer and octreotide for acromegaly.
One of the challenges with PLGA microspheres is ensuring uniform particle size and consistent drug loading. Peptron claims to have refined its microencapsulation process to minimize initial burst release and achieve zero-order release kinetics over extended periods. For a peptide like tirzepatide, which is prone to aggregation and chemical instability, the formulation must also include stabilizing excipients to prevent degradation during storage and after injection.
Peptron has not publicly disclosed detailed pharmacokinetic data for a monthly tirzepatide formulation. However, the company has a track record of licensing its technologies to larger pharmaceutical partners for other indications.
Camurus and the FluidCrystal Technology
Camurus, headquartered in Lund, Sweden, takes a different approach. Its proprietary FluidCrystal technology uses amphiphilic lipids that self-assemble into liquid crystalline structures when injected subcutaneously. These structures form a gel-like depot that entraps the peptide and releases it slowly as the lipid matrix gradually erodes or undergoes phase transition.
The FluidCrystal system has already been successfully applied to long-acting formulations of buprenorphine and octreotide. It offers several potential advantages over polymer microspheres: the formulation is liquid at room temperature, making injection easier and avoiding the need for reconstitution; the depot formation is controlled by the body’s own water content rather than polymer degradation rates; and the lipid components are generally well tolerated.
For a monthly obesity injection, Camurus would need to demonstrate that the FluidCrystal matrix can release tirzepatide at a steady rate for at least 28 days without forming a painful lump or causing local inflammation. Early-stage animal studies would typically involve measuring plasma drug levels over time and assessing injection site reactions.
The Licensing Race and Lilly’s Strategic Calculus
According to the Chosunbiz report, both Peptron and Camurus are actively competing to win a licensing deal with Eli Lilly. The report did not specify whether Lilly is conducting its own in-house monthly formulation work or if it is solely evaluating external partners.
For Lilly, there are several reasons to pursue a monthly dosing option. Patient adherence is a major factor in chronic obesity management. Weekly injections require patients to maintain a strict schedule, store the injector pen properly, and manage side effects that may fluctuate with each dose. A monthly shot could simplify the regimen and reduce the likelihood of missed doses. From a manufacturing perspective, fewer doses per patient per year could help alleviate production bottlenecks that have plagued the GLP-1 market since 2022, when demand for semaglutide and tirzepatide far outstripped supply.
However, a monthly formulation also brings new risks. If a patient experiences severe adverse effects after a monthly injection, there is no way to rapidly remove the drug from the body. Unlike small-molecule drugs that can be dialyzed or metabolized quickly, a depot formulation continues to release the active ingredient for weeks. Careful patient selection and dose titration would be critical.
Broader Industry Trends: Long-Acting GLP-1 Agonists
Lilly is not alone in seeking longer dosing intervals. Novo Nordisk, the maker of Wegovy and Ozempic, has been exploring monthly or even less frequent formulations of semaglutide. Other companies, including Viking Therapeutics, Pfizer, and Structure Therapeutics, have oral or once-daily candidates in development, but the market is clearly moving toward longer-acting injectables.
Monthly injections could also open new market segments. People who are averse to weekly self-injections might be more willing to accept a monthly visit to a healthcare provider for administration. This could expand access to obesity pharmacotherapy in primary care settings, where monthly visits are already routine for chronic disease management.
The manufacturing advantages are also significant. A monthly injection uses roughly one-quarter the number of doses per patient per year compared to a weekly injection. For a drug like tirzepatide, which is produced through recombinant DNA fermentation in E. coli, scaling up manufacturing is capital intensive. Reducing dose frequency could ease pressure on existing production lines and help stabilize supply.
Technical Hurdles and Regulatory Path
Formulating a GLP-1 agonist for monthly release presents unique challenges beyond those of traditional long-acting injectables. Peptides are less stable than small molecules and can undergo aggregation, hydrolysis, or oxidation during long-term storage. The depot must maintain drug integrity for the entire release period, which may require lyophilization or special excipients.
Additionally, the injection site must tolerate the depot for several weeks. Chronic inflammation, granuloma formation, or fibrosis could degrade the depot structure and alter release kinetics. Both Peptron and Camurus would need to conduct long-term biocompatibility studies to satisfy regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
If a licensing deal is reached, the partner would likely take on responsibility for scale-up, clinical development, and regulatory filing. Lilly could then incorporate the monthly formulation into its existing Mounjaro and Zepbound portfolios, potentially launching a new brand or expanding approved indications.
Market Implications and Competitive Landscape
The obesity drug market, already projected to exceed $100 billion annually by 2030, could see a major shift if monthly injections become available. Weekly injections have been the standard since 2005 when exenatide (Byetta) was the first GLP-1 agonist approved. Since then, longer-acting formulations such as exenatide once weekly (Bydureon) and dulaglutide (Trulicity) have shown that patients will adopt convenient regimens.
A monthly tirzepatide injection would be a direct competitor to any monthly semaglutide product Novo Nordisk might develop. It could also provide Lilly with a differentiation point in a crowded market. However, the timeline remains uncertain. Neither Peptron nor Camurus has announced a finalized deal with Lilly, and neither has published clinical data on a monthly tirzepatide formulation.
Frequently Asked Questions
Q: How does a monthly injection differ from a weekly one in terms of pharmacokinetics?
A: A weekly injection typically involves a solution that reaches peak concentration quickly and then declines over seven days. A monthly formulation uses a drug depot that releases the active ingredient slowly and at a controlled rate over 28 days. This requires advanced delivery technologies like polymer microspheres or lipid liquid crystals to maintain steady drug levels without large fluctuations.
Q: Are there any existing monthly injectable peptides for metabolic diseases?
A: Currently, no GLP-1 receptor agonists are approved for monthly dosing. The closest examples are long-acting formulations of octreotide (Sandostatin LAR) and leuprolide (Lupron Depot), used for acromegaly and cancer, respectively. Those peptides have very different stability profiles and target indications than GLP-1/GIP agonists.
Q: What are the risks of a monthly obesity injection that differ from weekly shots?
A: The main risk is the inability to quickly stop drug exposure if a patient has a severe adverse reaction. With weekly injections, stopping therapy halts further drug entry. With a monthly depot, the drug continues to release from the injection site for weeks. Careful patient selection, dose titration, and monitoring are essential to manage this risk.
Q: Who are Peptron and Camurus, and have they partnered with major pharma before?
A: Peptron is a South Korean biopharmaceutical company specializing in sustained-release drug delivery. It has licensing deals with other Asian pharmaceutical firms. Camurus is a Swedish biotech focused on lipid-based drug delivery, with approved products including a long-acting buprenorphine formulation for opioid dependence. Both have experience in peptide delivery but not specifically with GLP-1 agonists.